New schizophrenia drug shows promise in 6-week trial

NCT ID NCT02477020

Completed Symptom relief Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a new drug called TAK-063 can help people with schizophrenia who are having a sudden worsening of symptoms. 164 adults took either the drug or a placebo for 6 weeks. The main goal was to see if symptoms improved using a standard rating scale. The study is complete, and results will show if TAK-063 is safe and effective for short-term symptom control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Study site

Springdale, Alaska, United States
Study site

Culver City, California, United States
Study site

Lemon Grove, California, United States
Study site

Long Beach, California, United States
Study site

Pico Rivera, California, United States
Study site

Lauderhill, Florida, United States
Study site

Orlando, Florida, United States
Study site

Atlanta, Georgia, United States
Study site

Lake Charles, Louisiana, United States
Study site

St Louis, Missouri, United States
Study site

Las Vegas, Nevada, United States
Study site

Oklahoma City, Oklahoma, United States
Study site

Austin, Texas, United States
Study site

Dallas, Texas, United States
Study site

Houston, Texas, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.